With Cephalon Buy, Teva Bets on Brand Drugs and More In-House Innovation
If commodity generics and in-licensing deals are all the rage, then Teva just strapped on a fanny pack with its $6.8 billion acquisition of Cephalon. The deal is expected to skyrocket Teva’s brand drug...
View ArticleGenerics Win in an Express Scripts/Medco deal
As a preferred generics supplier to Medco’s mail-order business, Novartis’ Sandoz division, for one, should be waiting with bated breath – and champagne at the ready – for an FTC approval of Express...
View ArticleClik here to view.
Specialty Drugs and Reimbursement
To maximize return on investment, pharma must think strategically about reimbursement channels and how new specialty products will perform in one versus another. PMPY = Per Member, Per Year. Source:...
View ArticleClik here to view.
CEO Interview: Harvey Berger, Ariad Pharmaceuticals
Eight months into the launch of its first approved drug – Iclusig (ponatinib), a small molecule therapy indicated for two rare forms of leukemia – Ariad Pharmaceuticals’ principal founder and CEO...
View ArticleBig Pharma's "Firepower" Effectively Dropped by 20% in 2013, Says Report
Although Big Pharma’s ‘firepower’ increased last year by $100 billion, it declined in comparison with that of Big Biotech and specialty pharma, according to a new report from EY. EY’s Firepower Index...
View Article
